Secondary AML
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Jazz PharmaceuticalsCA - Palo Alto
1 programCPX-351N/A1 trial
Active Trials
NCT02533115Approved For Marketing
Trial Timeline
Clinical trial activity over time
2026
2027
2028
Tempusrebecsinib
Clinical Trials (2)
Total enrollment: 28 patients across 2 trials
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Start: Apr 2026Est. completion: Apr 202828 patients
Phase 1Not Yet Recruiting
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
N/AApproved For Marketing
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.